Simcere Pharmaceutical Group Limited
Simcere Pharmaceutical Group Limited engages in the research, development, manufacture, and sale of pharmaceutical products for distributors and pharmacy chains and other pharmaceutical manufacturers in China. It focusses on various therapeutic areas, in…
Biotechnology
CN, Nanjing [HQ]
Cash Flow Statement
8 Sheets · From 2023 to 2012Configuration
In Million CNY. Margins, Growth Rates In %
| Metric | 2012 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | |||||||||
| Operating Cash Flow (OCF) | 313.00 | 939.00 | 775.00 | 772.00 | 96.00 | -201.00 | 1,354.00 | 151.00 | |
| Operating Cash (Net) | 313.00 | 939.00 | 775.00 | 772.00 | 96.00 | -201.00 | 1,354.00 | 151.00 | |
| Accounts Receivable | 184.00 | -26.00 | -254.00 | -386.00 | -542.00 | -545.00 | 74.00 | -322.00 | |
| Accounts Payable | - - | - - | - - | 386.00 | 542.00 | 545.00 | -74.00 | - - | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | |
| Change | 190.00 | 244.00 | -55.00 | -290.00 | -462.00 | -769.00 | 79.00 | -946.00 | |
| Other WC | - - | 224.00 | -6.00 | -270.00 | -426.00 | -760.00 | 195.00 | -236.00 | |
| Investing Activities | |||||||||
| Used Cash (Net) | -65.00 | -508.00 | -472.00 | -592.00 | 529.00 | -435.00 | 68.00 | 1,087.00 | |
| Capital Expenditure | -73.00 | -292.00 | -335.00 | -507.00 | -352.00 | -209.00 | -678.00 | -979.00 | |
| Purchases of Investments | - - | -1,407.00 | -896.00 | -1,670.00 | -103.00 | -1,489.00 | -344.00 | -68.00 | |
| Sale/Maturity of Investment | - - | 804.00 | 1,154.00 | 974.00 | 764.00 | 451.00 | 824.00 | 949.00 | |
| Property, Plant, Equipment (P&PE) | -73.00 | -292.00 | -335.00 | -507.00 | -352.00 | -209.00 | -678.00 | -979.00 | |
| Acquisitions (Net) | - - | -10.00 | -20.00 | -154.00 | 120.00 | 44.00 | 335.00 | 906.00 | |
| Other Investing Activities | 7.00 | 397.00 | -374.00 | 764.00 | 100.00 | 767.00 | -68.00 | -51.00 | |
| Financing Activities | |||||||||
| Used Cash (Net) | -279.00 | -347.00 | -311.00 | -1,012.00 | -2,353.00 | -1,624.00 | -753.00 | -894.00 | |
| Debt Repayment | -1,252.00 | -843.00 | -982.00 | -2,025.00 | -1,824.00 | -2,463.00 | -1,184.00 | -68.00 | |
| Dividends Paid | - - | - - | -549.00 | -912.00 | - - | -391.00 | -391.00 | -419.00 | |
|
Common Stock
|
121 | - - | -1,862 | -2,391 | - - | - - | - - | 289 | |
| Issued | - - | -4.00 | 13.00 | 43.00 | 3,007.00 | - - | - - | - - | |
| Repurchased | -121.00 | -4.00 | 1,876.00 | 2,434.00 | - - | - - | - - | -289.00 | |
| Other Financing Activities | -279.00 | 500.00 | -48.00 | -554.00 | 1,170.00 | 1,230.00 | 821.00 | -35.00 | |
| Cash Balances | |||||||||
| Begin of Period | 209.00 | 489.00 | 572.00 | 1,187.00 | 354.00 | 3,270.00 | 973.00 | 1,658.00 | |
| End of Period | 178.00 | 572.00 | 1,187.00 | 354.00 | 3,270.00 | 973.00 | 1,657.00 | 2,007.00 | |
| Change | -31.00 | 83.00 | 615.00 | -832.00 | 2,915.00 | -2,297.00 | 684.00 | 348.00 | |
| Non-Cash Balances | |||||||||
| Depreciation and Amortization | 131.00 | 104.00 | 120.00 | 162.00 | 222.00 | 251.00 | 282.00 | 309.00 | |
| Stock Based Compensation | 20.00 | 15.00 | 5.00 | 14.00 | 32.00 | 62.00 | 138.00 | 12.00 | |
| Other | 125.00 | 30.00 | 8.00 | 70.00 | 73.00 | -29.00 | -25.00 | 5.00 | |
| Highlighted metrics | |||||||||
| Free Cash Flow (FCF) | 240.00 | 646.00 | 440.00 | 265.00 | -256.00 | -411.00 | 676.00 | -828.00 | |
| Cash Conversion Cycle (CCC) | 251.00 | 48.00 | 42.00 | 94.00 | 159.00 | 145.00 | 126.00 | 212.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
|||||||||
| Forex Effect on Cash | - - | - - | - - | - - | -63.00 | -35.00 | 15.00 | 4.00 |